Online inquiry

IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4054MR)

This product GTTS-WQ4054MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL36RN gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_012275.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26525
UniProt ID Q9UBH0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4054MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6069MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ14895MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ13448MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ9899MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ15733MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ3496MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ3760MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW